Plain-English translation of NCT05948813 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new medication called works better and is safer than a standard lung cancer drug called for patients with a specific type of lung cancer (non-small cell lung cancer with EGFR mutations) that has spread to the brain. You would be randomly assigned to take either the new medication or the existing treatment daily as a tablet. The study will compare how well each medication works and what side effects patients experience.
Current treatments for this type of lung cancer can help, but doctors want to know if this new medication might work even better, especially for patients whose cancer has reached the brain. This trial will help determine whether the medication is a good option for people facing this serious diagnosis.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the new medication (160 mg once daily) or the standard treatment (80 mg once daily) as an oral tablet. You will continue taking your assigned medication as long as your cancer does not worsen, you don't develop unmanageable side effects, or the study ends. Throughout the study, you will have regular visits to check how the medication is working, monitor your health, and watch for any side effects. The study involves about 420 people across multiple research centers.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
TYK Medicines, Inc
Enrollment target
~420 participants
Started
August 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yuankai Shi, MD
Cancer Institute/Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.